Shoulder Innovations (SI) Q4 2025 earnings review
Hyper-Growth Secured, But Operating Burn Deepens
Shoulder Innovations delivered a massive Q4, with revenue growth accelerating to 65% YoY ($14.4M). The company easily crushed its upwardly revised full-year guidance, finishing FY25 at $47.3M (+50% YoY). The growth engine is firing on all cylinders: implant system volumes are accelerating, and the core surgeon base expanded by 61%. However, the cost of this growth is steep. Operating expenses skyrocketed as the company absorbed public transition costs, ongoing litigation fees, and a new milestone payment for a robotics partnership, pushing the Q4 operating loss to $8.5M. The company is trading near-term profitability for aggressive market share capture, backed by a fortified $124M balance sheet.
🐂 Bull Case
Volume is compounding rapidly. Implant systems sold accelerated from 34% YoY growth in Q2 to 53% in Q3, and now 62% in Q4 (1,976 units). The surgeon adoption curve is exceptionally strong.
Despite rapid scaling, gross margins remained remarkably stable at 76.7% for Q4 (76.5% for the year). This proves the company maintains significant pricing power and manufacturing efficiency as volumes rise.
🐻 Bear Case
SG&A ballooned 79% YoY to $16.3M in Q4, significantly outpacing revenue growth. Unspecified litigation costs continue to act as an anchor on the path to profitability.
FY26 revenue guidance of $62M-$65M implies 31-37% growth. While objectively high, it represents a notable deceleration from the 65% exit velocity of Q4 and the 50% rate achieved in FY25.
⚖️ Verdict: 🟢
Bullish. The widening net loss is a characteristic feature of an early-stage, post-IPO MedTech company heavily investing in commercialization. With $124M in cash, 76%+ gross margins, and a 65% top-line acceleration rate, the fundamentals underlying the market share grab are overwhelmingly positive.
Key Themes
Surgeon Adoption Reaching Critical Mass
The primary catalyst for Shoulder Innovations' top-line explosion is its rapidly expanding user base. The company ended 2025 with 134 'core and contender' surgeons, an accelerating 61% YoY increase. Because core surgeons perform 9+ units per quarter, adding to this specific cohort compounds recurring revenue rapidly and explains the 62% surge in Q4 implant systems sold.
Robotics Integration via Interventional Systems
Management announced a strategic partnership with Interventional Systems to introduce a robotic platform for shoulder arthroplasty. This is a critical technological leap to compete with larger orthopedic incumbents. The initiative drove Q4 R&D expenses up 176% YoY to $3.2M due to an initial milestone payment, framing it as a near-term margin headwind but a massive long-term commercial driver.
Litigation and Commercial Expansion Crushing Margins
The bottom line is deteriorating. Q4 Adjusted EBITDA loss widened to $7.0M (from a $2.6M loss a year ago). The culprit is SG&A, which surged 79% YoY to $16.3M. Management explicitly cited higher legal costs related to ongoing litigation, alongside commercial headcount additions and public company costs. Until the legal overhang is resolved, SG&A will remain structurally inflated.
Rapid Pipeline Execution
The company is aggressively filling out its product portfolio. Following the Q3 full launch of the InSet 70 humeral stem, Q4 saw limited user releases for two major products: the InSet I-135RFX Humeral Stem (addressing primary, revision, and fracture indications) and the N-22 Humeral Head (targeting the metal hypersensitivity demographic). This expanding toolset makes SI a viable one-stop shop for ASCs.
Other KPIs
Stable compared to the end of Q3 ($137.3M), reflecting the massive cash injection from the Q3 IPO and convertible notes. With an annual Adjusted EBITDA burn of roughly $36M, this gives the company 3+ years of runway, practically eliminating near-term dilution risk.
Stable. Gross margins have hovered tightly between 76.2% and 76.9% all year. Maintaining premium margins while scaling unit volume by 62% YoY is a testament to strong pricing power and the operational efficiency of their two-tray ASC system.
Guidance
Decelerating. The midpoint ($63.5M) implies a 34% YoY growth rate. While this is a step down from the 50% growth achieved in FY25, it is a standard base-effect deceleration. Notably, SI initially guided FY25 to $42-$44M before ultimately delivering $47.3M, suggesting this initial FY26 range may be intentionally conservative.
Key Questions
Litigation Timeline and Impact
SG&A expenses remain heavily burdened by litigation costs. With the IP trial historically expected in 1H 2026, what are the expected quarterly legal spend run-rates leading up to the trial, and is there a path to settlement?
Robotics Platform Rollout
Following the milestone payment to Interventional Systems, what is the regulatory and commercial timeline for bringing the robotic platform to market, and how will it be priced?
ASC Mix Shift
In Q3, ASCs represented over 30% of your procedure mix. How did that metric evolve in Q4, and what ceiling do you see for ASC penetration over the next 12-24 months?